Discussion: The major TDRMs observed in this study have been reported in a previous study of HIV Drug Resistance among ART-failure individuals in Yunnan Province, which figured out mutations such as M184 V/I, K103 N, V106A, Y181C and G190A were common.
Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana.
Result: Three major DRAMs to NNRTIs were seen in 3 patients among the drug-naive participants; these DRAMs were K103 N, V106A and E138A.
Table: V106A
Discussion: K103 N and V106A are major mutations associated with NNRTIs conferring high-level HIV-1 drug resistance to NVP and EFV.
Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.
PMID: 29977795
2018
African journal of laboratory medicine
Result: Other NNRTI mutations, such as V90I, K103N, V106A/M, E138A, V179E, Y181C, Y188C/L and G190E were also found in one or two samples.
Table: V106A
Discussion: The mutations K101E, K103N, V106A/M, V179D/T, Y181C, G190A/E and H221Y to NNRTI were the most common minority mutations detected in these patients.
Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
PMID: 28481112
2017
Journal of medicinal chemistry
Abstract: Compound 25a was exceptionally potent against the whole viral panel, affording 3-4-fold enhancement of in vitro antiviral potency against WT, L100I, K103N, Y181C, Y188L, E138K, and K103N+Y181C and 10-fold enhancement against F227L+V106A relative to the reference drug etravirine (ETV) in the same cellular assay.
HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals.
Abstract: All of the identified SDRMs belonged to the non-nucleoside reverse transcriptase inhibitors (NNRTIs) class, including K103 N and V106A, which were found in three patients.
HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China.
Abstract: Among them, 7 polymorphisms (L74I, K103N, V106A, Y181C, G190A, T215I and P225H) were known to be drug resistance mutations, 7 polymorphisms (E6D, E35D, S37N, I93L, E169D, T200V and T200E were considered to be potential drug resistance mutations, and 6 polymorphisms (T39A, K43E, S68N, Q197K, T200V and E22
Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.
PMID: 27750153
2017
European journal of medicinal chemistry
Abstract: Furthermore, most compounds maintained high activity agaist various single HIV-1 mutants (L100I, K103N, E138K, Y181C) as well as one double mutant (F227L/V106A) with EC50 values in low-micromolar to double-digit nanomolar concentration ranges.
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
HIV mutation literature information.
PMID: 
2018
BMC infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT